VolgendeVolgende gids
AI klinische beslissingsondersteuning voor artsen
Industrieën
Gids voor de samenleving
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply.
The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
Clinical decision support software provides information or recommendations to support healthcare decisions. FDA’s guidance explains how the agency assesses software functions under the applicable statutory criteria. Some functions may be excluded from the device definition when they meet specific conditions, including that a health professional can independently review the basis for recommendations. Other functions, including certain patient-specific analyses or device functions, may remain subject to oversight. The assessment is about what a particular software function does, its intended user, and how the output is used. A product can contain multiple functions with different regulatory status. A tool that presents evidence for a clinician to review is not automatically treated the same as software that directs diagnosis or treatment. FDA guidance also notes that functions intended for patients or caregivers may be assessed differently from clinician-facing support. Manufacturers should define each function and provide information that supports independent review where relevant. Clinicians should understand what inputs and evidence support a recommendation, the intended population, and limitations. A generated explanation is not itself proof of the underlying basis. Check current FDA guidance and product labeling for the specific function. This guide summarizes concepts and does not determine regulatory status for a product. Preserve examples of intended use and evidence that support the analysis, and revisit it when users, claims, or outputs change. Keep patient-facing and clinician-facing functions distinct in requirements and documentation.
Catastrofale en alledaagse schade door AI hangt af van wie de risico's begrijpt en wie kan handelen.
Publieke en professionele geletterdheid bepalen of een krachtig veiligheidsbeleid politiek mogelijk is.
Duidelijke verklaringen verminderen de kans op hypes, laboratorium-PR en vaag ethisch theater.
Decision-support products increasingly use machine learning and generative models, creating new questions about explainability and how clinicians review evidence. FDA guidance is updated as laws and technology change. Developers should monitor current agency materials and preserve a function-level analysis. Care teams need training to interpret outputs and should retain clinical judgment even when a tool is authorized. Developers should design interfaces that make the evidence and limitations easy to inspect, not merely generate a plausible explanation. Monitor outcomes and user feedback.
A clinician reviews sources and rationale behind a recommendation before acting.
A software team separates administrative reminders from patient-specific treatment recommendations.
A hospital confirms whether a function is intended for health professionals or patients.
A developer maps the product’s intended use to the criteria in current FDA guidance.
Existentieel risico behandelen als sciencefiction, terwijl capaciteiten zich vermenigvuldigen.
De veiligheid van oppervlakteproducten verwarren met uitlijning onder hoge autonomie.
Hierdoor blijven niet-Engelstalige en niet-deskundige doelgroepen alleen bronnen van lage kwaliteit over.
Afzonderlijke risico's voor productschade, misbruik en verlies van controle/verkeerde uitlijning.
Vraag welk bewijs uw kijk op tijdlijnen en ernst zou veranderen.
Geef de voorkeur aan primaire bronnen en concrete evaluaties boven marketingclaims.
Identificeer één actiepad: carrière, beleid, financiering of vaardigheden – niet alleen bewustwording.
Free newsletter
Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply. The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
Regulatory analysis depends on the function and how it is used.
Regulatory assessment is not necessarily product-wide and uniform.
Function-specific documentation supports assessment and use.
CDS supports decisions and does not replace professional review.
Blijf leren
Er zijn meer handleidingen voor dit onderwerp geselecteerd
VolgendeVolgende gids
AI klinische beslissingsondersteuning voor artsen
Industrieën